Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + Bortezomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma with Extramedullary Disease
2024-514963-24-00Phase 2Authorised
- Sponsor
- European Myeloma Network
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of daratumumab, bortezomib, cyclophosphamide and dexamethasone in multiple myeloma (MM), sponsored by European Myeloma Network. Primary endpoint: Proportion of patients with CR. Planned start Sep 2024; status: authorised.
02
Drugs
daratumumabbortezomibcyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-514963-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514963-24-00.